Advertisement.
Advertisement.
Advertisement
Advertisement.
BIOR Biora Therapeutics Inc
28,770
| Market Cap | $23.54M |
| Volume | 61,493.00 |
| 52-Wk High | $3.95 |
| 52-Wk Low | $0.475 |
Biora Therapeutics announces interim results of BT-600 clinical trial
The Fly•4 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Mean Plasma Tofacitinib Concentration
Following administration of a single oral dose of 5 mg and 10 mg BT-600
All pharmacokinetic endpoints were achieved, with a PK profile...
Globe Newswire•4 months ago
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...
Globe Newswire•4 months ago
Biora Therapeutics announces $6M registered direct offering and concurrent private placement...
Seeking Alpha - Healthcare•4 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly•4 months ago
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into...
Globe Newswire•4 months ago
Biora Therapeutics (NASDAQ:BIOR Get Free Report) and DURECT (NASDAQ:DRRX Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...
Ticker Report•4 months ago
Related Stocks: NAS:BIOR...
GuruFocus•4 months ago
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower...
Globe Newswire•4 months ago